Advances in Medicinal Chemistry
Seiten
1999
JAI Press Inc. (Verlag)
978-0-7623-0064-8 (ISBN)
JAI Press Inc. (Verlag)
978-0-7623-0064-8 (ISBN)
Comprises of six chapters on a range of topics in medicinal chemistry, including molecular modeling, structure-based drug design, organic synthesis, peptide conformational analysis, biological assessment, structure-activity correlation, and lead optimization.
Volume 4 of Advances in Medicinal Chemistry is comprised of six chapters on a wide range of topics in medicinal chemistry, including molecular modeling, structure-based drug design, organic synthesis, peptide conformational analysis, biological assessment, structure-activity correlation, and lead optimization. Chapter 1 presents an account about amino acid-based peptide mimetics corresponding to b-turn, loop, helical motifs in proteins as a probe of ligand-receptor and ligand-enzyme molecular interactions. Chapter 2 addresses new facets of the medicinal chemistry of the important anticancer drug Taxol® (paclitaxel). Chapter 3 relates an account of the search for new drugs for the treatment of malaria based on the natural product artemisinin. Chapter 4 applies computational chemistry to the evaluation of compound libraries for biological testing. Chapter 5 describes the construction of a 3-dimensional molecular model of the human thrombin receptor, the first protease-activated G-protein coupled receptor (PAR-1), as a means to explore the intermolecular contacts involved in agonist peptide recognition. Finally, Chapter 6 describes the research conducted at Merck on inhibitors of farnesyl transferase as a potential treatment for human cancers.
Volume 4 of Advances in Medicinal Chemistry is comprised of six chapters on a wide range of topics in medicinal chemistry, including molecular modeling, structure-based drug design, organic synthesis, peptide conformational analysis, biological assessment, structure-activity correlation, and lead optimization. Chapter 1 presents an account about amino acid-based peptide mimetics corresponding to b-turn, loop, helical motifs in proteins as a probe of ligand-receptor and ligand-enzyme molecular interactions. Chapter 2 addresses new facets of the medicinal chemistry of the important anticancer drug Taxol® (paclitaxel). Chapter 3 relates an account of the search for new drugs for the treatment of malaria based on the natural product artemisinin. Chapter 4 applies computational chemistry to the evaluation of compound libraries for biological testing. Chapter 5 describes the construction of a 3-dimensional molecular model of the human thrombin receptor, the first protease-activated G-protein coupled receptor (PAR-1), as a means to explore the intermolecular contacts involved in agonist peptide recognition. Finally, Chapter 6 describes the research conducted at Merck on inhibitors of farnesyl transferase as a potential treatment for human cancers.
Preface. Novel peptide mimetic building blocks and strategies for efficient lead finding. Recent advances in the medicinal chemistry of taxoid anticancer agents. Synthesis and structure-activity relationships of peroxidic antimalarials based on artemisinin. Design of compound libraries for detecting and pursuing novel small molecule leads. A theoretical model of the human thrombin receptor (PAR-1), the first known protease-activated G-protein-coupled receptor. Farnesyl transferase inhibitors: design of a new class of cancer chemotherapeutic agents.
| Erscheint lt. Verlag | 1.4.1999 |
|---|---|
| Reihe/Serie | Advances in Medicinal Chemistry |
| Verlagsort | Oxford |
| Sprache | englisch |
| Maße | 156 x 234 mm |
| Gewicht | 680 g |
| Themenwelt | Studium ► 2. Studienabschnitt (Klinik) ► Pharmakologie / Toxikologie |
| Naturwissenschaften ► Chemie | |
| ISBN-10 | 0-7623-0064-7 / 0762300647 |
| ISBN-13 | 978-0-7623-0064-8 / 9780762300648 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Buch | Hardcover (2024)
Thomas Karow (Verlag)
CHF 79,95
Buch | Hardcover (2022)
Urban & Fischer in Elsevier (Verlag)
CHF 138,60
